May 28, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Dillon Hagius
| RE: | Oncotelic Therapeutics, Inc. (CIK: 0000908259) | |
| Registration Statement No. 333-256448 on Form S-1 (the “Registration Statement”) |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Oncotelic Therapeutics, Inc. hereby requests the acceleration of the effective date of the above referenced Registration Statement so that it will become effective at 5:00 p.m. Eastern Time, June 2, 2021, or as soon thereafter as practicable.
| Oncotelic Therapeutics, Inc. | ||
| By: | /s/ Vuong Trieu | |
| Name: | Vuong Trieu | |
| Title: | Chief Executive Officer | |